(Q37972703)

26 August 2017

Diagnostic and prognostic molecular biomarkers for prostate cancer (English)

1 reference

26 August 2017

0 references

0 references

1 reference

Glen Kristiansen

1

1 reference

26 August 2017

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

60

1 reference

26 August 2017

1

1 reference

26 August 2017

125-141

1 reference

26 August 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Molecular predictors of response to therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Molecular predictive and prognostic markers in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Minimal adenocarcinoma in prostate needle biopsy tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

p63 is a prostate basal cell marker and is required for prostate development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Characterization of a prostate carcinoma mucin-like antigen (PMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

P504S: a new molecular marker for the detection of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Abundant expression of AMACR in many distinct tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Disease- and cell-specific expression of GP73 in human liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

GP73, a novel Golgi-localized protein upregulated by viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Gene expression analysis of prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Fatty acid synthase: a metabolic oncogene in prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ETS gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Antibody-based detection of ERG rearrangement-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Diagnostic biomarkers of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Steroid hormone receptor expression in male breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Prostein expression is highly restricted to normal and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ERG rearrangement metastasis patterns in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ERG rearrangement in small cell prostatic and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ERG gene rearrangements are common in prostatic small cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Expression of NKX3.1 in normal and malignant tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

NKX3.1 as a marker of prostatic origin in metastatic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Critical review of prostate cancer predictive tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Results of conservative management of clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

20-year outcomes following conservative management of clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Active surveillance for early-stage prostate cancer: review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Active surveillance for favorable risk prostate cancer: rationale, risks, and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or “insignificant”

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Molecular sampling of prostate cancer: a dilemma for predicting disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

The genomic complexity of primary human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Epigenetics in prostate cancer: biologic and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

MicroRNAs in cancer: small molecules with a huge impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Delineation of prognostic biomarkers in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Gene expression profiling predicts clinical outcome of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Defining aggressive prostate cancer using a 12-gene model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Tumor cell proliferation and survival in patients with prostate cancer followed expectantly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Tissue microarray sampling strategy for prostate cancer biomarker analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ERG rearrangement is present in a subset of transition zone prostatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Prospective Multi-Institutional Study Evaluating the Performance of Prostate Cancer Risk Calculators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

Do Clinically Insignificant Tumors of the Prostate Exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2011.04083.X

10.1111/J.1365-2559.2011.04083.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22212082